EHR

CHIME24 Fall Forum: Clinical Informatics Leaders to Share Why the ‘Time is Now’ to Embrace Next-Generation Clinical Decision Support

FDB-led panel will discuss how they are advancing CDS in their institutions to deliver more personalized and actionable guidance to…

1 year ago

AMD Global Telemedicine and Carefluence Announce Strategic Partnership to Enhance Telehealth Interoperability

The collaboration delivers greater value to clients for seamless data exchange, enhanced continuity of care, and improved clinical outcomes.CHELMSFORD, MA…

1 year ago

Immutep Quarterly Activities Report Q1 FY25

Positive feedback received from US FDA regarding the planned TACTI-004 Phase III in first-line non-small cell lung cancer successfully concluding…

1 year ago

Breckenridge Distillery and Flaviar Partner to Release Dad’s Stash Whiskey in Support of No-Shave November, Raising Funds for Fight Colorectal Cancer (Fight CRC)

BRECKENRIDGE, Colo., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Breckenridge Distillery, one of the most-awarded craft distilleries in the U.S. and a…

1 year ago

Aignostics Secures $34 Million Series B to Enhance Precision Medicine with AI

Investments will support new product offerings, US expansion, and development of pathology foundation models. BERLIN and NEW YORK, Oct. 29,…

1 year ago

Epic Welcomes Oracle Health to TEFCA

Interoperability is a team sport, and Epic looks forward to Oracle Health getting off the sidelines and joining the game.…

1 year ago

3Aware and RQM+ Forge Partnership to Enhance MedTech Compliance and Innovation

INDIANAPOLIS, IN / ACCESSWIRE / October 28, 2024 / 3Aware, a pioneer in real-world evidence (RWE) solutions for the medical…

1 year ago

Novartis oral Fabhalta® (iptacopan) sustained clinically meaningful results at one year in Phase III C3 glomerulopathy (C3G) trial 

New APPEAR-C3G data show Fabhalta sustained proteinuria reduction at 12 months1Upon Fabhalta initiation, improvement observed in estimated glomerular filtration rate…

1 year ago

Pivotal VALIANT Results Presented at Kidney Week Highlight Strength of Pegcetacoplan Treatment Effect in Patients with C3G / Primary IC-MPGN

Statistically significant 68% (p<0.0001) proteinuria reduction compared to placebo, with reduction observed as early as Week 4 All secondary endpoints…

1 year ago

Pharos Announces $5M Seed Round To Automate Hospital Quality Reporting

SAN FRANCISCO, Oct. 25, 2024 /PRNewswire/ -- Hospital quality reporting platform Pharos announced today the close of its oversubscribed $5M seed round led…

1 year ago